

sáb 20 de sep
|Wisconsin State Capitol Building
Prostate Cancer Awareness Forum & Panel Discussion
Horario y ubicación
20 sep 2025, 9:00 a.m. – 10:00 a.m.
Wisconsin State Capitol Building, 2 E Main St, Madison, WI 53702, USA
Acerca del evento
Event video now available. Please click below.
The 100 Black Men of Madison, Inc. is raising the awareness for early detection and treatment of Prostate Cancer, particularly in the African American community. Our Forum will combine our collective voices and leverage our individual organizational influence to increase awareness of this disease that threatens and drastically impacts males and their families. To eliminate the African American Prostate Cancer Disparity, the 100 Black Men of Madison, Inc. acknowledge and agree that knowledge is the best defense against prostate cancer as we endeavor to help reduce confusion about how to detect, treat, and cope with Prostate Cancer among men at highest risk.
Keynote Speakers: Dr. Douglas McNeel, MD PhD & Dr. Joshua Lang, MD, MS
Dr. Douglas McNeel
Dr. Douglas McNeel, MD PhD is a tenured Professor of Medicine at the University of Wisconsin, Madison, WI. He is a genitourinary medical oncologist with a clinical and laboratory translational research focus on prostate cancer immunology. Since 1997 he and his laboratory have studied vaccines
for prostate cancer, specifically identifying antigens to target in vaccines, evaluating DNA vaccines and their mechanisms of action and resistance, and translating these studies to human clinical trials.
Dr. Joshua Lang
Dr. Joshua Lang is a faculty member in the Division of Hematology, Medical Oncology and Palliative Care in the Department of Medicine. He is the co-director of the internal medicine residency's Physician-Scientist Training Program (PSTP) and a lecturer in several didactic series for medical students, internal medicine residents and hematology/oncology fellows. He is also the director of the UW Carbone Cancer Center's circulating biomarker core and liquid biospecimen team, the co-leader of its tumor microenvironment program, and the clinical co-chair of its precision medicine molecular tumor board.
